Compugen Ltd.

CGEN Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.

2.08 0.08 +4.00%
Market cap
$187.6M
P/E
5.5×
Fwd P/E
−7.2×
Dividend yield
—
F-score
7/9
Altman Z
−0.37
Beneish M
−1.59
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
5.63 5.76 4.14 0.00

+8 more quarters

P/S ratio
2.74 2.77 1.96 19.92
P/FCF ratio
5.06 1.98 1.41 3.08
P/Operating CF
(9.23) 6.37 4.52 (7.41)
P/B ratio
2.28 1.96 1.39 1.34
Price to Tangible BV
2.28 1.96 1.39 1.34
EV/Sales
1.04 0.91 (0.04) 7.45
EV/EBITDA
2.55 2.16 0.00 0.00
EV/Operating CF
1.90 0.65 (0.03) 1.14
EV/FCF
1.93 0.65 (0.03) 1.15
Quick Ratio
5.72 6.23 6.56 4.38
Current Ratio
5.72 6.23 6.56 4.38
Net Debt/EBITDA
14.18 14.97 (2.60) 10.91
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.50 0.56 0.54 0.06
Operating CF/Net income
3.13 0.00 0.56 0.00
Capex/Depreciation
(0.26) — 30.50 —
Research and Development Expense of Revenue
242.43% 318.80% 8.23% 306.72%
Selling, General and Administrative Expense of Revenue
93.66% 111.76% 3.28% 123.43%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Graham Net Nets
0.39 0.43 0.66 0.25
Graham Number
2.83 0.00 3.03 0.00
Earnings Yield
17.76% 17.37% 24.18% (20.41%)
Free Cash Flow Yield
19.77% 50.49% 71.14% 32.42%
Revenue per Share
0.03 0.02 0.72 0.02
Operating CF per Share
(0.23) 0.00 0.34 0.00
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.23) 0.00 0.34 0.00
Cash per Share
1.32 1.43 1.56 0.92
Shareholders Equity per Share
0.94 1.01 1.10 0.47
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.94 1.01 1.10 0.47
Free Cash Flow
(21.98) — 31.33 —
Working Capital
106.78 115.25 125.45 68.64
Capital Expenditures
(0.04) — (0.30) —
Net Current Asset Value
79.78 86.78 94.18 34.90
EV/EBIT
2.55 2.16 0.00 0.00
Capex to Sales
0.01 0.00 0.00 0.00
Price to Operating Income
6.69 6.56 4.56 0.00
Other line items
Average Receivables
3.25 2.74 2.56 2.48
Average Payables
2.00 2.45 2.93 —
Average Assets
147.47 130.65 135.78 110.68
Average Common Equity
73.54 — 84.15 —

Fold the line items

Columns are period end dates